Spark Therapeutics to Participate in Multiple Upcoming Conferences
November 02, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Nov. 02, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics to Host Conference Call on Tuesday, Nov. 7 at 8:30 a.m. ET to Discuss Third Quarter 2017 Results
October 31, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 31, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, will host a...
FDA Advisory Committee Unanimously Recommends Approval of Investigational LUXTURNA™ (voretigene neparvovec) for Patients with Biallelic RPE65-mediated Inherited Retinal Disease
October 12, 2017 16:51 ET
|
Spark Therapeutics, Inc.
Investigational LUXTURNA has the potential to be both the first pharmacologic treatment for an inherited retinal disease (IRD) and the first gene therapy for a genetic disease in the United States ...
Spark Therapeutics (ONCE) Trading of Stock Halted as FDA Advisory Committee Reviews Investigational Gene Therapy
October 12, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 12, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...
Spark Therapeutics to Participate in Multiple Conferences in October
October 03, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Oct. 03, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Further Expands Gene Therapy Expertise with Appointment of Federico Mingozzi, Ph.D., as Chief Scientific Officer
September 25, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Enters into Licensing Agreement with Genethon
September 20, 2017 07:30 ET
|
Spark Therapeutics, Inc.; Genethon
PHILADELPHIA and EVRY, France, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic...
Spark Therapeutics Announces Publication of Study Confirming Novel Test’s Validity, Reliability and Ability to Detect Change in Functional Vision
September 06, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Sept. 06, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics to Participate in Multiple Conferences in September
August 30, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 30, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, today...
Spark Therapeutics Recognized as One of Philadelphia’s “Best Places to Work” by the Philadelphia Business Journal
August 11, 2017 07:30 ET
|
Spark Therapeutics, Inc.
PHILADELPHIA, Aug. 11, 2017 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced...